Skip to main content
SpringerLink
Log in

Current State of Medical Therapies for Peripheral Vascular Disease

  • Chapter
Vascular Complications in Human Disease

  • 609 Accesses

Abstract

Atherosclerotic narrowing of the lower limb arteries is the most common cause of peripheral vascular disease (PVD), affecting 27 million people in Europe and North America.1 The prevalence of PVD increases with age, and with an aging population it is becoming an increasing burden in the West.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Belch JJ, Topol EJ, Agnelli G, et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003;163:884–892.

    Article  PubMed  Google Scholar 

  2. Dormandy J, Mahir M, Ascady G, et al. Fate of the patient with chronic leg ischemia. A review article. J Cardiovasc Surg (Torino) 1989;30:50–57.

    CAS  Google Scholar 

  3. Critical limb ischemia: management and outcome. Report of a national survey. The Vascular Surgical Society of Great Britain and Ireland. Eur J Vasc Endovasc Surg 1995;10:108–113.

    Google Scholar 

  4. Tierney S, Fennessy F, Hayes DB. ABC of arterial and vascular disease. Secondary prevention of peripheral vascular disease. BMJ 2000;320:1262–1265.

    Article  PubMed  CAS  Google Scholar 

  5. Lewis DR, Bullbulia RA, Murphy P, et al. Vascular surgical intervention for complications of cardiovascular radiology: 13 years’ experience in a single centre. Ann R Coll Surg Engl 1999;81:23–26.

    PubMed  CAS  Google Scholar 

  6. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001;344:1608–1621.

    Article  PubMed  CAS  Google Scholar 

  7. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation 1995;91:1472–1479.

    PubMed  CAS  Google Scholar 

  8. Hirsch AT, Treat-Jacobson D, Lando HA, et al. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc Med 1997;2:243–251.

    PubMed  CAS  Google Scholar 

  9. Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 1999;159:337–345.

    Article  PubMed  CAS  Google Scholar 

  10. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340–2346.

    Article  PubMed  CAS  Google Scholar 

  11. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:23–33.

    Google Scholar 

  12. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998;81:333–335.

    Article  PubMed  CAS  Google Scholar 

  13. Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003;108:1481–1486.

    Article  PubMed  CAS  Google Scholar 

  14. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.

    Google Scholar 

  15. Goldhaber SZ, Manson JE, Stampfer MJ, et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians’ Health Study. Lancet 1992;340:143–145.

    Article  PubMed  CAS  Google Scholar 

  16. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994;308:159–168.

    Google Scholar 

  17. Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:17–24.

    Article  PubMed  CAS  Google Scholar 

  18. Ahimastos AA, Lawler A, Reid CM, et al. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med 2006;144:660–664.

    PubMed  CAS  Google Scholar 

  19. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317–1324.

    Article  PubMed  CAS  Google Scholar 

  20. Rehring TF, Sandhoff BG, Stolcpart RS, et al. Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg 2005;41:816–822.

    Article  PubMed  Google Scholar 

  21. Sun B, Le SN, Lin S, et al. New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation. J Cardiovasc Pharmacol 2002;40:577–585.

    Article  PubMed  CAS  Google Scholar 

  22. Thompson PD, Zimet R, Forbes WP, et al. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002;90:1314–1319.

    Article  PubMed  CAS  Google Scholar 

  23. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000;109:523–530.

    Article  PubMed  CAS  Google Scholar 

  24. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999;159:2041–2050.

    Article  PubMed  CAS  Google Scholar 

  25. Regensteiner JG, Ware JE, Jr., McCarthy WJ, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: metaanalysis of six randomized controlled trials. J Am Geriatr Soc 2002;50:1939–1946.

    Article  PubMed  Google Scholar 

  26. Dettelbach HR, Aviado DM. Clinical pharmacology of pentoxifylline with special reference to its hemorrheologic effect for the treatment of intermittent claudication. J Clin Pharmacol 1985;25:8–26.

    PubMed  CAS  Google Scholar 

  27. Moher D, Pham B, Ausejo M, et al. Pharmacological management of intermittent claudication: a meta-analysis of randomised trials. Drugs 2000;59:1057–1070.

    Article  PubMed  CAS  Google Scholar 

  28. Lehert P, Riphagen FE, Gamand S. The effect of naftidrofuryl on intermittent claudication: a meta-analysis. J Cardiovasc Pharmacol 1990;16(Suppl. 3):S81–S86.

    PubMed  Google Scholar 

  29. Lehert P, Comte S, Gamand S, et al. Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol 1994;23(Suppl.3):S48–S52.

    PubMed  Google Scholar 

  30. Diamantopoulos EJ, Grigoriadou M, Ifanti G, Raptis SA. Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication. Int Angiol 2001;20(4):337–344.

    PubMed  CAS  Google Scholar 

  31. De Backer TLM, Vander Stichele RH, Bogaert MG. Buflomedil for intermittent claudication. The Cochrane Database of Syst Rev 2000:CD000988.

    Google Scholar 

  32. Trubestein G, Balzer K, Bisler H, et al. Buflomedil in arterial occlusive disease: results of a controlled multicenter study. Angiology 1984;35(8):500–505.

    Article  PubMed  CAS  Google Scholar 

  33. Diamantopoulos EJ, Grigoriadou M, Ifanti G, Raptis SA. Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication. Int Angiol 2001;20(4):337–344.

    PubMed  CAS  Google Scholar 

  34. Grant SM, Goa KL. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischemia and extracorporeal circulation procedures. Drugs 1992;43(6):889–924.

    Article  PubMed  CAS  Google Scholar 

  35. Reiter M, Bucek RA, Stumpflen A, Minar E. Prostanoids for intermittent claudication. Cochrane Database Syst Rev 2004:CD000986.

    Google Scholar 

  36. Creutzig A, Lehmacher W, Elze M. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV. Vasa 2004;33:137–144.

    Article  PubMed  CAS  Google Scholar 

  37. Intravenous pentoxifylline for the treatment of chronic critical limb ischemia. The European Study Group. Eur J Vasc Endovasc Surg 1995;9:426–436.

    Google Scholar 

  38. Efficacy and clinical tolerance of parenteral pentoxifylline in the treatment of critical lower limb ischemia. A placebo controlled multicenter study. Norwegian Pentoxifylline Multicenter Trial Group. Int Angiol 1996;15:75–80.

    Google Scholar 

  39. Smith FB, Bradbury AW, Fowkes FGR. Intravenous naftidrofuryl for critical limb ischemia. Cochrane Database Syst Rev 2000:CD002070.

    Google Scholar 

  40. Boger RH, Bode-Boger SM, Thiele W, et al. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998;32:1336–1344.

    Article  PubMed  CAS  Google Scholar 

  41. Bode-Boger SM, Boger RH, Alfke H, et al. L-Arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation 1996;93:85–90.

    PubMed  CAS  Google Scholar 

  42. Boger RH, Bode-Boger SM, Thiele W, et al. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997;95:2068–2074.

    PubMed  CAS  Google Scholar 

  43. Tsikas D, Boger RH, Sandmann J, et al. Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett 2000;478:1–3.

    Article  PubMed  CAS  Google Scholar 

  44. Tsui JC, Baker DM, Biecker E, et al. Evidence for the involvement of endothelin-1 but not urotensin-II in chronic lower limb ischemia in man. Eur J Vasc Endovasc Surg 2003;25:443–450.

    Article  PubMed  CAS  Google Scholar 

  45. Korn JH, Mayes M, Matucci CM, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985–3993.

    Article  PubMed  CAS  Google Scholar 

  46. Humbert M, Cabane J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology (Oxford) 2003;42:191–193.

    Article  PubMed  CAS  Google Scholar 

  47. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97:1114–1123.

    PubMed  CAS  Google Scholar 

  48. Makinen K, Manninen H, Hedman M, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002;6:127–133.

    Article  PubMed  CAS  Google Scholar 

  49. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002;360:427–435.

    Article  PubMed  Google Scholar 

  50. Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002;359:2053–2058.

    Article  PubMed  CAS  Google Scholar 

  51. Rajagopalan S, Mohler ER, III, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003;108:1933–1938.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vascular Unit, Department of Surgery, Royal Free and University College Medical School, Hampstead, London, UK

    Janice C. S. Tsui MD, MRCS & Daryll M. Baker PhD, FRCS

Authors
  1. Janice C. S. Tsui MD, MRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daryll M. Baker PhD, FRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Royal Free and University College Medical School, London, UK

    David Abraham PhD (Professor of Cellular and Molecular Biology) (Professor of Cellular and Molecular Biology)

  2. Clinical Biochemistry, Royal Free and University College Hospital Medical School, London, UK

    Michael Dashwood PhD (Principal Research Fellow) (Principal Research Fellow)

  3. The National Pulmonary Hypertension Unit, Royal Free Hospital, London

    Clive Handler BSc, MD, MRCP, FACC, FESC (Consultant in Pulmonary Hypertension and Honorary Senior Lecturer) (Consultant in Pulmonary Hypertension and Honorary Senior Lecturer)

  4. Department of Medicine, Royal Free and University College Hospital Medical School, London, UK

    Clive Handler BSc, MD, MRCP, FACC, FESC (Consultant in Pulmonary Hypertension and Honorary Senior Lecturer) (Consultant in Pulmonary Hypertension and Honorary Senior Lecturer)

  5. Royal Free Hospital, London, UK

    Gerry Coghlan MD, FRCP (Consultant Cardiologist) (Consultant Cardiologist)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag London Limited

About this chapter

Cite this chapter

Tsui, J.C.S., Baker, D.M. (2008). Current State of Medical Therapies for Peripheral Vascular Disease. In: Abraham, D., Dashwood, M., Handler, C., Coghlan, G. (eds) Vascular Complications in Human Disease. Springer, London. https://doi.org/10.1007/978-1-84628-919-4_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-919-4_11

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-918-7

  • Online ISBN: 978-1-84628-919-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation